Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT06784648 |
| Title | Different Doses of BI-1607 in Combination with Pembrolizumab and Ipilimumab, in Participants with Unresectable or Metastatic Melanoma |
| Recruitment | Recruiting |
| Gender | both |
| Phase | Phase Ib/II |
| Variant Requirements | No |
| Sponsors | BioInvent International AB |
| Indications | |
| Therapies | |
| Age Groups: | senior | adult |
| Covered Countries | GBR |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| Sarah Cannon Research Institute UK | RECRUITING | London | Greater London | W1G 6AD | United Kingdom | Details |
| Velindre Cancer Centre | NOT_YET_RECRUITING | Cardiff | Wales | CF14 2TL | United Kingdom | Details |
| The Christie NHS Foundation Trust | NOT_YET_RECRUITING | Manchester | M20 4BX | United Kingdom | Details |